Cleveland BioLabs, Inc.

Controlling cell death to protect human life

NASDAQ: CBLI Company Overview
www.cbiolabs.com Cleveland BioLabs, Inc. is a drug discovery and development company
leveraging its proprietary discoveries around programmed cell death to
CORPORATE HEADQUARTERS treat cancer and protect normal tissues from exposure to acute stresses.
Cleveland BioLabs, Inc. The Company has strategic partnerships with the Cleveland Clinic, Roswell
73 High St. Park Cancer Institute, ChemBridge Corporation and the Armed Forces
Buffalo, NY 14203 Radiobiology Research Institute.
T:716-849-6810 | F:716-849-6820
www.cbiolabs.com Technology
Proprietary technology based on ability to pharmacologically suppress or
FINANCIAL SUMMARY (4/22/10) induce programmed cell death (apoptosis) for therapeutic purpose. CBLI’s
Shares Outstanding: 27 M unique understanding that cancer cells and normal cells die from different
Market Cap: $107M mechanisms enables one to treat them separately.
52 Wk High: $6.35
52 Wk Low: $2.26 Two families of Compounds:
Recent Price: $3.97 • Protectans - drug candidates that protect healthy tissues from acute
stresses such as radiation and chemotherapy
Fiscal Year End: December 31
• Curaxins - anticancer agents that can act as monotherapy drugs or in
Intellectual Property combination with other existing anticancer therapies
- Exclusive licenses from the Cleveland Clinic
and Roswell Park Cancer Institute (RPCI) Lead Compounds
on drug candidates and technology
- 14 sets of patent applications filed Protectan CBLB502 (mitigator of radiation & chemotherapy toxicities)
- First US & European patents for CBLB502 • Potential applications include reduction of radiation or chemotherapy
granted toxicities in cancer patients, and protection from Acute Radiation
Syndrome (ARS) in defense or nuclear emergency scenarios
Partnerships
• Successfully concluded first of Phase I healthy volunteer
- Cleveland Clinic
trials– only Phase I safety trials required for approval via FDA
- Roswell Park Cancer Institute (RPCI)
animal efficacy rule for ARS
- ChemBridge Corp.
- Armed Forces Radiobiology Research • Submission for FDA approval for ARS indication anticipated late 2010
Institute (AFRRI) • $25.9 million in development contracts from DoD and HHS
• Potential sales to US government (DoD and HHS) and foreign
Resources govt.s
- Headcount: 35 full-time employees
- Headquarters and Research located in • Science publication on CBLB502’s potential efficacy as radiation
recently renovated, fully equipped three- protector for defense or medical use
story research building on Roswell Park • Phase I/II medical study to start 2010 in head and neck cancer
campus, Buffalo, NY patients for reduction of radiation toxicities
- Development team located in Chicago, IL
- Supporting infrastructure: all state-of-the- Protectan CBLB612 (stem cell induction & mobilization)
art core research facilities of RPCI • Potential applications include accelerated hematopoietic recovery
during chemotherapy and during donor preparation for bone marrow
Funding History transplantation
- $5 million private placement, February 2010 • Direct and synergistic comparisons to $5 billion market
- $5.4 million private placement, March 2009 leading drug G-CSF (Neupogen/Neulasta) demonstrated better
- $30 million private placement, March 2007 efficacy
- $10 million IPO, July 2006
• License agreement for China with Zhejiang Hisun
- $6 million Series A round, March 2005
Pharmaceutical - $1.65 million upfront, 10% royalties
- Up to $5 million in grant funding from RPCI
- $50M+ in development contracts and grants
Curaxins (anti-cancer)
from DoD, BARDA/HHS, NIH, NIAID and
NASA • Small molecules, simultaneously targeting three signaling pathways
frequently deregulated in cancer
Contact: • Phase II proof of concept demonstrated activity and safety in
Director Corporate Development and hormone-refractory prostate cancer trial with first generation
compound
Communications
Rachel Levine • New mechanistic discoveries point to additional combination therapies
T: 646-284-9439 | F: 646-284-9494 • Next generation proprietary compounds up to 100x more efficacious,
E: rlevine@cbiolabs.com expected to advance towards human trials through $18 million JV
partnership
Under The Private Securities Litigation Reform Act of 1995: Except for historical information contained herein, the statements in this factsheet are forward-looking
statements that are made pursuant to the safe harbor provisions of the Private Securities Act of 1995. Forward-looking statements involve known and unknown risks and
uncertainties, which may cause a company's actual results, performance and achievement in the future to differ materially from forecasted results, performance, and
achievement. These risks and uncertainties are described in the Company's periodic filings with the Securities and Exchange Commission.